Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities

Cytometry Part A

Volumn 73, Issue 11, 2008, Pages 1043-1049

  Wölfl, Matthias ^a,b,d   Kuball, Jürgen ^b,c   Eyrich, Matthias ^a   Schlegel, Paul G ^a   Greenberg, Philip D ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

4 1BB; Adoptive immunotherapy; Antigen specific T cells; CD137; Immune monitoring

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; EPITOPE; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CELL ISOLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; HUMAN; IMMUNOSTIMULATION; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANTIGENS, CD137; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION;

EID: 55949097109     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20594     Document Type: Review

References (32)

1. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989;86:1963-1967.
2. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
3. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002;168:4897-4906.
4. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-4888.
5. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002;3:536-541.
6. Dawicki W, Watts TH. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol 2004;34:743-751.
7. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007;110:201-210.
8. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003;3:431-437.
9. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 1998;34:207-215.
10. Maino VC, Maecker HT. Cytokine flow cytometry: A multiparametric approach for assessing cellular immune responses to viral antigens. Clin Immunol 2004;110:222-231.
11. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
12. Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 2006;310:40-52.
13. Mehrotra S, Stevens R, Zengou R, Chakraborty NG, Butterfield LH, Economou JS, Dorsky DI, Mukherji B. Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res 2003;63:5607-5614.
14. Chattopadhyay PK, Price DA, Harper TF, Betts MR, Yu J, Gostick E, Perfetto SP, Goepfert P, Koup RA, De Rosa SC, Bruchez MP, Roederer M. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med 2006;12:972-977.
15. Kwon BS, Tan KB, Ni J, Oh KO, Lee ZH, Kim KK, Kim YJ, Wang S, Gentz R, Yu GL, Harrop J, Lyn SD, Silverman C, Porter TG, Truneh A, Young PR. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997;272:14272-14276.
16. Hural J, Horton H, Huang Y, McElrath MJ, De Rosa SC. Validation of intracellular cytokine staining assays for evaluation of t cell responses in vaccine trials. 2008; Presented at the third MASIR conference, La Plagne, France.
17. Nomura L, Maino VC, Maecker HT. Standardization and optimization of multiparameter flow cytometric studies. Cytometry A 2008;73A: in press. DOI: 10.1002/cyto.a.20602, (this issue).
18. Wehler TC, Nonn M, Brandt B, Britten CM, Grone M, Todorova M, Link I, Khan SA, Meyer RG, Huber C, Hartwig UF, Herr W. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007;109:365-373.
19. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007;9:1-17.
20. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk HD. T-cell epitope mapping by flow cytometry. Nat Med 1998;4:975-978.
21. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005;201:1031-1036.
22. Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 2005;7:109-115.
23. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003;102:2292-2299.
24. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006;108:1797-1808.
25. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W. Depletion of alloreactive T cells via CD69: Implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 2006;37:297-305.
26. Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008;14:99-109.
27. Assenmacher M. Cytokine capture system (CCS) for enrichment of T cells for adoptive transfer. 2008; Presented at the third MASIR conference, La Plagne, France.
28. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 2001;166:3174-3183.
29. Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W, Taylor PA. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol 2000;165:4901-4909.
30. Beetz S, Marischen L, Kabelitz D, Wesch D. Human gamma delta T cells: Candidates for the development of immunotherapeutic strategies. Immunol Res 2007;37:97-111.
31. O'Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res 2007;38:237-250.
32. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.